A Post-marketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated with Tyvaso (Treprostinil) Inhalation Solution
Study on Investigational Treatment for Hypertension
Not Recruiting
18 years - 100 years
All
Phase
N/A
Brief description of study.
No Description Available
Detailed description of study
No Description Available
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:Pulmonary Arterial Hypertension
Age:
18 years - 100 years
Gender: All
Who can participate: Adults aged 18-65 with a diagnosis of hypertension are eligible to participate. Key inclusion criteria include stable medication regimen and no history of severe cardiovascular events.
Study details: Participants will receive either the investigational treatment or a placebo. The study will involve regular monitoring of blood pressure and health assessments to evaluate treatment outcomes.
Updated on
19 Feb 2024.
Study ID: 1107006396
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
